Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAR-20SP in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06313957Phase 1Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2024
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LUCAR-20SP in B-cell non-Hodgkin lymphoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Dose-limiting toxicity rate at 2 years, Treatment-emergent adverse events at 2 years and 3 more. Started Mar 2024; status: recruiting.
02
Drugs
LUCAR-20SP
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06313957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313957.